Acro Biomedical Co., Ltd. carries a market capitalization of 1.56M, placing it among publicly traded companies globally. Its enterprise value stands at 1.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.56M |
| Enterprise Value | 1.56M |
Acro Biomedical Co., Ltd. currently has 60.04M shares outstanding.
| Shares Outstanding | 60.04M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.05 |
| P/TBV Ratio | -3.65 |
| P/FCF Ratio | -6.98 |
| P/OCF Ratio | -6.98 |
Acro Biomedical Co., Ltd. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -18.19 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -926.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 0.26 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Acro Biomedical Co., Ltd.'s stock has gained approximately 3614.28585% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | 3614.28585% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.01 |
| Average Volume (20 Days) | N/A |
EBITDA reached -205,361.00, while operating income came in at -205,361.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -205,361.00 |
| Pretax Income | -134,619.00 |
| Net Income | -134,619.00 |
| EBITDA | -205,361.00 |
| EBIT | -205,361.00 |
| Earnings Per Share (EPS) | 0.00 |
Total book value stands at -32.74M, with working capital of -427,235.00 providing operational flexibility.
| Cash & Cash Equivalents | 3,873.00 |
| Total Debt | N/A |
| Net Debt | -3,873.00 |
| Equity (Book Value) | -32.74M |
| Book Value Per Share | -0.55 |
| Working Capital | -427,235.00 |
Acro Biomedical Co., Ltd. produced -223,592.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -223,592.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -223,592.00 |
| FCF Per Share | 0.00 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14.55 |
| FCF Yield | -14.32 |
Acro Biomedical Co., Ltd. posts an Altman Z-Score of -12,162.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12,162.60 |